ImmuCell (ICCC) Set to Announce Quarterly Earnings on Thursday

ImmuCell (NASDAQ:ICCC) is scheduled to be announcing its earnings results after the market closes on Thursday, May 9th. Investors interested in registering for the company’s conference call can do so using this link.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($0.15) EPS for the quarter. ImmuCell had a negative net margin of 33.05% and a negative return on equity of 21.79%. The company had revenue of $5.10 million during the quarter.

ImmuCell Trading Up 1.2 %

NASDAQ:ICCC opened at $5.09 on Tuesday. The business’s 50-day moving average is $5.15 and its two-hundred day moving average is $5.01. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.73 and a quick ratio of 0.87. The firm has a market capitalization of $39.80 million, a PE ratio of -6.79 and a beta of 0.60. ImmuCell has a 12 month low of $4.26 and a 12 month high of $6.05.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.